Targeted drug-carrying bacteriophages

Details Targeted drug-carrying bacteriophages Targeted drug-carrying bacteriophages

2011-07-26

2011-07-26

Lucas, Zachariah (Department: 1648)

Chemistry: molecular biology and microbiology

Virus or bacteriophage, except for viral vector or...

C424S093200

Reexamination Certificate

active

07985573

ABSTRACT:
The present invention relates to the field of drug delivery. More specifically, the invention relates to the preparation and use of a bacteriophage conjugated through a labile
on labile linker or directly to at least 1,000 therapeutic drug molecules such that the drug molecules are conjugated to the outer surface of the bacteriophage. The bacteriophage optionally displays on its coat a ligand that endows it with specificity towards target cells. Thus, there is provided a targeted, high-capacity drug delivery system useful for the treatment of various pathological conditions.

REFERENCES:
patent: 5427908 (1995-06-01), Dower et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 6159728 (2000-12-01), Stockley et al.
patent: 6387397 (2002-05-01), Chen et al.
patent: 6448083 (2002-09-01), Larocca et al.
patent: 6451527 (2002-09-01), Larocca et al.
patent: 6485902 (2002-11-01), Waddell et al.
patent: 2002/0034733 (2002-03-01), Lohning
patent: 2002/0044922 (2002-04-01), Mardh
patent: 2003/0216338 (2003-11-01), Merril et al.
patent: 2004/0011648 (2004-01-01), Paul et al.
patent: 2004/0014652 (2004-01-01), Trouet et al.
patent: 2004/0121974 (2004-06-01), March
patent: 2004/0161431 (2004-08-01), Carlton et al.
patent: 2005/0255462 (2005-11-01), Barrett et al.
patent: WO 91/17271 (1991-11-01), None
patent: WO 93/00434 (1993-01-01), None
patent: WO 98/05344 (1998-02-01), None
patent: WO 00/33888 (2000-06-01), None
patent: WO 00/53236 (2000-09-01), None
patent: WO 01/05950 (2001-01-01), None
patent: WO 01/23619 (2001-04-01), None
patent: WO 02/076498 (2002-10-01), None
patent: WO 02/077182 (2002-10-01), None
patent: WO 03/035611 (2003-05-01), None
patent: WO 03/086276 (2003-10-01), None
patent: WO 2004/052274 (2004-06-01), None
patent: WO 2004/062677 (2004-07-01), None
Hart et al., Cell Binding and Internalization by Filamentous Phage Displaying a Cyclic Arg-Gly-Asp-containing Peptide, Journal of Biological Chemistry, 1994, 269(17):12468-12474.
Larocca et al. , Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage, FASEB J. 13, 727-734 (1999).
Bastien et al., “Protective Immune Responses Induced by the Immunization of Mice with a Recombinant Bacteriophage Displaying an Epitope of the Human Respiratory Syncytial Virus,” Virology 234, 118-122 (1997).
Benhar et al., “Highly Efficient Selection of Phage Antibodies Mediated by Display of Antigen as Lpp-OmpA′ Fusions on Live Bacteria,” J. Mol. Biol. (2000) 301, 893-904.
Benhar et al., “Tumor Targeting by Antibody-Drug Conjugates,” CRC Press, Inc., 1997, 73-85.
Brown et al., “RNA Bacteriophage Capsid-Mediated Drug Delivery and Epitope Presentation,” Intervirology 2002; 45:371-380.
Clark et al., “Bacteriophage-mediated nucleic acid immunization,” FEMS Immunology and Medical Microbiology 40 (2004) 21-26.
Delmastro et al., “Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration,” Vaccine, vol. 5, No. 11, pp. 1276-1285, 1997.
Felnerova et al., “Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs,” Current Opinion in Biotechnology 2004, 15:518-529.
Garcea et al., “Virus-like particles as vaccines and vessels for the delivery of small molecules,” Current Opinion in Biotechnology 2004, 15:513-517.
Haimovich et al., “Protein-Bacteriophage Conjugates: Application in Detection of Antibodies and Antigens,” Science, vol. 164, pp. 1279-1280, Jun. 13, 1969.
Haus-Cohen et al., “Disruption of P-Glycoprotein Anticancer Drug Efflux Activity by a Small Recombinant Single-Chain Fv Antibody Fragment Targeted to an Extracellular Epitope,” Int. J. Cancer: 109, 750-758 (2004).
Kassner et al., “Genetic Selection of Phage Engineered for Receptor-Mediated Gene Transfer to Mammalian Cells,” Biochemical and Biophysical Research Communications 264, 921-928 (1999).
Larocca et al., “Receptor-mediated gene transfer by phage-display vectors: applications in functional genomics and gene therapy,” DDT vol. 6, No. 15, 793-801, Aug. 2001.
Larocca et al., “Receptor-Targeted Gene Delivery Using Multivalent Phagemid Particles,” Molecular Therapy vol. 3, No. 4, 476-484, Apr. 2001.
Mazor et al., “Humanization and epitope mapping of the H23 anti-MUC1 monoclonal antibody reveals a dual epitope sepecificity,” Molecular Immunology 42 (2005) 55-69.
Menendez et al., “Immunisation with phage-displayed variable region 2 from meningococcal PorA outer membrane protein induces bactericidal antibodies againstNeisseria meningitides,” Immunology Letters 39 (2001) 143-148.
Meola et al., “Derivation of Vaccines From Mimotopes—Immunologic Properties of Human Hepatitis B Virus Surface Antigen Mimotopes Displayed on Filamentous Phage,” The Journal of Immunology, 1995, 154: 3162-3172.
Merrill et al., “Long-circulating bacteriophage as antibacterial agents,” Proc. Natl. Acad. Sci. USA, vol. 93, pp. 3188-3192, Apr. 1996.
Mikawa et al., “Surface Display of Proteins on Bacteriophage λ Heads,” J. Mol. Biol. (1996) 262, 21-30.
Nakamura et al, “The effect of an agglutogen on virus infection: biotinylated filamentous phages and avidin as a model,” Federation of European Biochemical Societies Letters 520 (2002) 77-80.
Nakamura et al., “A Visualization Method of Filamentous Phage Infection and Phage-Derived Proteins inEscherichia coliUsing Biotinylated Phages,” Biochemical and Biophysical Research Communications 289, 252-256 (2001).
Phalipon et al., “Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics,” Eur. J. Immunol. 1997, 27: 2620-2625.
Poul et al., “Selection of Tumor-Specific Internalizing Human Antibodies from Phage Libraries,” J. Mol. Biol. (2000) 301, 1149-1161.
Poul et al., “Targeted Gene Delivery to Mammalian Cells by Filamentous Bacteriophage,” J. Mol. Biol. (1999) 288, 203-211.
Sulica et al., “Detection of Antibody-Like Structures on Cell Surfaces with Chemically Modified Bacteriophages,” The Journal of Immunology vol. 106, No. 3, Mar. 1971.
Summers, “Bacteriophage Therapy,” Annu. Rev. Microbiol. 2001. 55:437-51.
Ulbrich et al., “Polymeric anticancer drugs with pH-controlled activation,” Advanced Drug Delivery Reviews 56 (2004) 1023-1050.
Urbanelli et al., “Targeted Gene Transduction of Mammalian Cells Expressing the HER2
eu Receptor by Filamentous Phage,” J. Mol. Biol. (2001) 313, 965-976.
White et al., “Antibody-Targeted Immunotherapy for Treatment of Malignancy,” Annu. Rev. Med. 2001, 52:125-45.
Woiwode et al., “Synthetic Compound Libraries Displayed on the Surface of Encoded Bacteriophage,” Chemistry & Biology, vol. 10, 847-858, Sep. 2003.

Affiliated with

Also associated with

Rating

Targeted drug-carrying bacteriophages does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeted drug-carrying bacteriophages, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted drug-carrying bacteriophages will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2646787